Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 2, 2009, Pages 235-239

  Busse, Kristin H ^a   Hadigan, Colleen ^b   Chairez, Cheryl ^b   Alfaro, Raul M ^a   Formentini, Elizabeth ^a   Kovacs, Joseph A ^a   Penzak, Scott R ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Building 10 ^*  (United States)

Author keywords

Drug interaction; Gemfibrozil; HIV; Lopinavir ritonavir

Indexed keywords

GEMFIBROZIL; LOPINAVIR PLUS RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-HIV AGENTS; ANTILIPEMIC AGENTS; DRUG ANTAGONISM; FEMALE; GEMFIBROZIL; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PLASMA; PYRIMIDINONES; RITONAVIR;

EID: 70349680871     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b0610e     Document Type: Article

References (37)

1. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)- infected adults receiving antiretroviral therapy: recommendations of the HIV medicine association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37: 613-627.
2. Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS. 2005;19:641-652.
3. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med. 2005;6:296-402.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
5. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007; 45:1074-1081.
6. DAD Study Group, Friis-Moller N, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
7. Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs. 2002;2:91-106.
8. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002;16:2195-2200.
9. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS. 1999;13:868-869.
10. Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352: 1031-1032.
11. Silverberg MJ, Leyden W, Hurley L. Response to newly prescribed lipidlowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150:301-313.
12. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008;10:61-70.
13. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998;34:155-162.
14. Spence JD. Metabolism of fibric acid derivatives. Clin Pharmacokinet. 1998;34:419-420.
15. Lopid [package insert]. New York, NY: Pfizer; Sept 2006.
16. Mano Y, Usui T, Kamimura H. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007;35:2040-2044. (Pubitemid 350005193)
17. Rowland A, Elliot DJ, Williams JA, et al. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos. 2006;34:1055-1062.
18. Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UGT1A4, UGT1A8 and UGT1A10. Drug Metab Dispos. 2008 Oct 6 [Epub ahead of print].
19. van der Lee MJ, Dawood L, Hadewych JM. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80:159-168.
20. Sheehan NL, Brouillette MJ, Delisle MS, et al. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother. 2006;40:147-150.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008:1-128. Available at: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed October 10, 2008.
22. Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 1995;76: 80A-83A.
23. Forland SC, Feng Y, Cutler RE. Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol. 1990;30: 29-32.
24. Evans JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol. 1987;27:994-1000.
25. Forland SC, Chaplin L, Cutler RE. Assay of gemfibrozil in plasma by-high performance-liquid chromatography. Clin Chem. 1987;33:1938.
26. Todd PA, Ward A. Gemfibrozil a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs. 1988;36:314-339. (Pubitemid 18224502)
27. de Salcedo I, Gorringe AL, Silva JL, et al. Gemfibrozil in a group of diabetics. Proc Roy Soc Med. 1976;69:64-70.
28. Cortese C, Abate G, Averna M, et al. An open label multicenter study to evaluate the efficacy and tolerability of gemfibrozil in elderly hyperlipidemic patients. Nutr Metab Cardiovasc Dis. 1997;7:30-37.
29. Kaukola S, Manninen V, Mälkönen M, et al. Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. Acta Med Scand. 1981;209:69-73.
30. Mussoni L, Mannucci L, Sirtori C, et al. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis. 2000;148:397-406.
31. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir-ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-578.
32. Nakagomi-Hagihara R, Nakai D, Tokui T, et al. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica. 2007;37:474-486.
33. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007;81:362-370.
34. Hamberger C, Barre J, Zini R, et al. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res. 1986;6:441-449.
35. Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2008.
36. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998; 35:275-291.
37. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004;36:1034-1040.